BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint (Q6626777)
From MaRDI portal
 | This is the item page for this Wikibase entity, intended for internal use and editing purposes. Please use this page instead for the normal view: BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint |
scientific article; zbMATH DE number 7933752
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint |
scientific article; zbMATH DE number 7933752 |
Statements
BIPSE: a biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint (English)
0 references
29 October 2024
0 references
Bayesian adaptive design
0 references
biomarker
0 references
dose finding
0 references
immune response
0 references
immunotherapy
0 references
phase I/II trial
0 references
progression-free survival
0 references
risk-benefit tradeoff
0 references
subgroups
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
0 references
